Emerging therapeutics for acute myeloid leukemia (AML) have evolved from disparate sources. In addition to oncogene, epigenetic, or cytokine pathway-directed therapies (discussed in other chapters), recent research has defined an eclectic collection of novel opportunities in leukemia treatment. These ...
Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity. Despite the advances in our understanding of its pathobiology, the chemotherapy-directed management has remained largely unchanged in the past 40 years. However, various novel agents have demonstrated clinical activity,...
Medicine, University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA Abstract: Acute myeloid leukemia (AML) is a hematologic malignancy that carries a poor prognosis and has garnered few treatment advances in the last few decades. ...
Laubach J,Rao AV.Current and emerging strategies for the managementof acute myeloid leukemia in the elderly〔J〕.The Oncologist. 2008Current and emerging strategies for the managementof acute myeloid leukemia in the elderly〔J〕. Laubach J,Rao AV. The Oncologist . 2008...
The pace of innovation of multiple myeloma therapy in recent years is remarkable with the advent of monoclonal antibodies and the approval of novel agents with new mechanisms of action. Emerging therapies are on the horizon for clinical approval with sig
With the recent successes of immune-based therapies in lymphoid malignancies it is expected that myeloid malignancies might similarly benefit. No known leukemia-specific cell surface antigens exist; all are shared in some way with their normal counterparts or other normal cells. One side effect of ...
Emerging Molecular and Immune Therapies in Acute Myeloid LeukemiaPrajwal BodduHagop KantarjianFarhad Ravandiand Naval Daver
Emerging therapies for acute myeloid leukemia Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity. Despite the advances in our understanding of its pathobiology, the ... C Saygin,HE Carraway - 《Journal of Hematology & Oncology》 被引量: 37发表: 2017年 Review of...
Immunotherapy in the form of immune checkpoint blockade (ICB) has revolutionized the treatment of various solid organ cancers; however, the widespread success of these therapies remains limited [1]. Currently, the most prominent ICB agents are monoclonal antibodies (mAbs) that block the co-inhibitory...
Acute myeloid leukemia (AML) is an aggressive, fast-growing cancer beginning inside bone marrow and spreading into the blood system, most often occurring in immature white blood cells. It has the lowest five-year survival rate among other types of leukemia and if left untreated, it can be fat...